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ABBREVIATIONS 
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FL  Femur length  
HC  Head circumference  
iPTB  Iatrogenic preterm birth 
POP study Pregnancy Outcome Prediction study 
PTB  Preterm birth 
sPTB  Spontaneous preterm birth 
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ABSTRACT  
Previous studies have suggested an association between fetal growth restriction and 
the risk of spontaneous preterm birth (sPTB). However, addressing this association 
is methodologically challenging. We conducted a prospective cohort study of 
nulliparous women with a singleton pregnancy in Cambridge, UK, 2008-2012. 
Ultrasonic fetal biometry was performed at 20 weeks of gestation as per routine 
clinical care. Participants also had blinded research ultrasonography at ~28 weeks. 
Biometric measurements were expressed as gestational age-adjusted z-scores. 
Fetal growth velocity was quantified by change in z-score between 20 and 28 weeks. 
Risk of sPTB, defined as delivery ≥28 and <37 weeks associated with labor in the 
absence of induction, was analysed using cause-specific Cox regression. 98 (2.5%) 
of 3,892 women had sPTB. When compared to the rest, the lowest decile of growth 
velocity of fetal femur between 20 and 28 weeks was associated with increased risk 
of sPTB (hazard ratio 2.37; 95% confidence interval: 1.43, 3.93; P<0.001). 
Adjustment for maternal characteristics was without material effect (hazard ratio: 
2.50; 95% confidence interval: 1.50, 4.14; P<0.001). There were no significant 
associations between other fetal measurements and risk of sPTB. To conclude, slow 
growth velocity of fetal femur is associated with an increased risk of sPTB.  
KEYWORDS 
Fetal biometry, fetal growth, growth velocity, spontaneous preterm birth.
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In the attempt to achieve the Millennium Development Goals, a global effort has 
been made to address the preventable causes of maternal and child mortality and to 
improve maternal and child health (1-4). As notable gains are being made, poorly 
understood causes, such as preterm birth (PTB), are contributing to an increasingly 
large proportion of maternal and child morbidity and mortality (5). The World Health 
Organization estimates that approximately 15 million babies are born preterm each 
year, out of which 1 million die, making prematurity the leading cause of neonatal 
death and the second leading cause of under-5 mortality worldwide (5, 6). 
Importantly, this figure is on the rise, with increases noted both in the number of 
iatrogenic and spontaneous PTBs (iPTB and sPTB, respectively)(5-8). The 
pathophysiology of sPTB is poorly understood (5, 7, 9, 10). Better understanding of 
the mechanisms might allow screening and intervention.  
 
Previous studies have shown associations between placental biomarkers and sPTB, 
including pregnancy-associated plasma protein A, alpha-fetoprotein, and 
corticotropin releasing hormone (11-17). However, the mechanistic link with the risk 
of sPTB is unclear. A number of studies have described relationships between fetal 
growth restriction (FGR) and the risk of sPTB. As FGR is associated with some of 
the same biomarkers (11-18), it could be on the causal pathway linking biomarker 
levels to sPTB. Growth restricted fetuses are often iPTBs, but less is known about 
the direct relationship between specific aspects of fetal growth patterns and the 
timing of sPTB (19-21).  
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A handful of studies have directly explored the relationship between fetal growth and 
sPTB. Some lack a clear definition of abnormal fetal growth, using birth weight or 
birth weight for gestational age as a proxy, which does not fully capture the process 
of growth in utero (22-25). Others have used ultrasound measures of fetal biometry 
at one time point, which provides a snapshot of fetal size but not the process of 
growth (26-30). In some cases, gestational age was measured by the last menstrual 
period (LMP), which decreases reliability of classification of prematurity (26, 28, 31). 
Importantly, many of the studies based on fetal growth as measured by 
ultrasonography have not explicitly mentioned blinding of measurements of fetal 
growth (13, 22-33), and some have also not specifically distinguished between iPTB 
and sPTB (34). Some studies have not reported individual biometric measurements 
but only the estimated fetal weight. Varying reference standards have been used and 
different cut-offs have been applied to define FGR. The studies vary in their design, 
and analytic methods e.g. logistic regression (13-16, 22-25, 28, 30, 33), linear 
regression (13, 31) or time-to-event analysis (35).  
 
In the present study, we used data from the Pregnancy Outcome Prediction (POP) 
study, a prospective cohort study of nulliparous women with a viable singleton 
pregnancy in Cambridge, UK, where women had serial blinded ultrasonography 
through pregnancy (36). Previous analyses of the POP study data have addressed 
the utility of universal ultrasonography as a screening test for FGR (37). In the 
present analysis, we investigate the association between early fetal growth and the 
subsequent risk of sPTB. 
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METHODS  
 
Study Population 
The Pregnancy Outcome Prediction study was a prospective cohort study of 
nulliparous women with a viable singleton pregnancy, based at the Rosie Hospital in 
Cambridge, UK. The study was approved by the Cambridge Local Research Ethics 
Committee (reference number 07/H0308/163). A full study protocol and the study 
cohort have been described elsewhere (36, 37). 
 
Briefly, women attending the Rosie Hospital meeting the study criteria (nulliparous, 
viable singleton pregnancy) were invited to enrol from 14 January 2008 to 31 July 
2012. Written informed consent was obtained by research midwives. In addition to 
the routine ultrasound scans at approximately 12-14 (for dating) and 20 weeks (for 
anomaly) weeks of gestational age, women underwent ultrasonography for the 
purposes of research at 28 and 36 weeks of gestational age. Participants and their 
care providers were blinded to the results of these scans, unless a major incidental 
finding was observed (major congenital anomaly, placenta previa, severe 
oligohydramnios, or non-cephalic presentation at 36 weeks).  
 
Gestational age was defined by ultrasound at the time of the dating scan. Maternal 
age was recorded at recruitment, maternal weight was measured at the dating scan 
appointment and maternal height was measured at the 20-week appointment. Body 
mass index (BMI) was calculated from weight and height. Information on maternal 
characteristics were collected either through a computer assisted questionnaire at 
the 20-week scan, from examination of the clinical case record, or through linkage to 
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the hospital’s electronic databases (marital status, previous spontaneous and 
therapeutic abortion, ethnicity, smoking status, age at leaving full time education and 
Index of Multiple Deprivation (IMD) 2007 score based on residential area (37)). 
 
Participants who withdrew or delivered elsewhere were excluded from the study. 
Additional exclusion criteria for the purposes of this analysis were stillbirths, 
pregnancies ending before 28 weeks of gestational age, defaults from any scans and 
history of essential hypertension or pre-existing diabetes mellitus. 
 
Statistical analysis 
Wilcoxon’s rank sum test was used to compare continuous variables and Pearson’s 
Chi-squared test or Fisher’s exact test were used to compare binary outcomes. Fetal 
growth was assessed by (a) z-scores of ultrasound measures of fetal biometry at 20 
and 28 weeks of gestational age, and (b) fetal growth velocity, defined as change in 
z-score of fetal biometry between 20 and 28 weeks of gestational age. Z-scores 
were adjusted for gestational age, estimated within the POP study using the method 
outlined by Altman & Chitty (1994) (38). Measures of fetal biometry included head 
circumference (HC), abdominal circumference (AC), femur length (FL), estimated 
fetal weight (EFW, calculated using the Hadlock equation (39)), HC:AC ratio, and 
AC:FL ratio (37). Additionally, z-scores were calculated with respect to the recently-
published INTERGROWTH-21st references for fetal growth (40) where the given 
measurement was reported (EFW, and HC:AC and AC:FL ratios were not reported). 
sPTB was defined as birth before 37 weeks of gestational age in the absence of 
induction of labor or elective caesarean section. Preliminary analyses included 
logistic regression on sPTB, excluding iPTBs. Linearity of associations and 
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interactions between fetal biometry and maternal characteristics on sPTB were 
tested using the likelihood ratio test.  
 
Cause-specific Cox regression was used to estimate the risk of sPTB with respect to 
each of the measures of fetal biometry or fetal growth velocity. The at-risk period for 
sPTB was defined as 28 +0/7 – 36+6/7 weeks of gestational age. The number of 
deliveries <28 weeks was very small and these pre-dated the 28 week scan. 
Clinically indicated preterm deliveries were treated as censored at the time of 
delivery. The analysis on sPTB was repeated using competing risks regression (Fine 
and Gray model) treating indicated preterm deliveries as competing events. Each 
growth measure was analysed (1) on its own in relation to sPTB and (2) adjusted for 
maternal characteristics. Records with missing values were excluded from the 
regression analysis.  
 
We further examined the relationship between fetal biometry and the risk of sPTB by 
dichotomising biometric and growth velocity measures into the extreme decile of 
change associated with slowest growth versus the other 9 deciles. In most cases the 
lowest decile was clearly the extreme decile associated with poor growth. However, 
elevated HC:AC ratio is associated with poor fetal growth and analysis of this 
measure compared the highest decile with the other nine. In addition to regression 
analyses, cumulative incidence curves were produced using the competing risks 
method for each group and the population attributable fraction (PAF) related to the 
extreme decile was calculated using the cause-specific method. All analyses were 
performed using Stata version 14.0 (StataCorp, Texas). 
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RESULTS  
 
Out of 4,512 women enrolled in the study, a total of 620 were excluded due to one or 
more of the following reasons: formally withdrawn (n=67), delivered elsewhere 
(n=255), stillbirths (n=12), pregnancies ending prior to 28 weeks of gestational age 
(n=42), defaulted from any scan (n=184), reported prior primary hypertension (n=73) 
or diabetes mellitus (n=15). A total of 3892 women were included in the analyses.  
 
The characteristics of the study population are described by the birth type (Table 1). 
98 (2.5%) births were sPTB and 59 (1.5%) were iPTB (including 3 women with 
ruptured membranes whose labor was induced only after 3 days of rupture), and 
data on the nature of 9 (0.2%) births was missing. Women who had term deliveries 
were taller, but were similar regarding age, BMI, the number of previous 
spontaneous and therapeutic abortions, ethnicity and indicators of socio-economic 
status.  
 
When the results of fetal biometry at 20 weeks were analysed as continuous 
variables, the risk of sPTB was directly associated with EFW (Table 2). A one SD 
increase in EFW was associated with 26% increase in the risk of sPTB after 
adjustment for maternal characteristics. At 28 weeks, the risk of sPTB was inversely 
associated with the FL and was directly associated with the ratio of AC:FL (Table 2). 
A one SD increase in these measures was associated with a 19% decrease and a 
23% increase in the risk of sPTB, respectively. However, both associations were 
attenuated by adjustment for maternal characteristics, and were no longer 
statistically significant. We next assessed the relationship between growth velocity 
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between the 20 and 28 week scan and the risk of sPTB (i.e. the change in the z-
score of paired measurements between the two scans, with lower values 
representing smaller relative measurements at the time of the second scan). When 
analysed as continuous variables, higher growth velocity of the FL and EFW were 
associated with a decreased risk of sPTB (Table 2). A one SD increase in these 
measures was associated with a 27% decrease and a 21% decrease in the risk of 
sPTB, respectively. Neither association was affected by adjustment for maternal 
characteristics. All associations were very similar between the cause-specific and 
competing risks regression and when the INTERGROWTH-21st reference standard 
was employed (Table 3).  
 
When biometric measurements were analysed comparing the extreme decile 
associated with poor growth, there was no association between any measurement at 
28 weeks and the risk of sPTB. When the growth velocity was assessed, babies in 
the lowest decile of FL growth velocity between 20 and 28 weeks of gestational age 
had a 2 to 3 fold risk of sPTB (Table 4, Figure 1). Adjustment for maternal 
characteristics was without material effect, and 12% (95% confidence interval [CI]: 
3%, 21%) of the sPTBs were estimated to be attributable to fetuses in the lowest 
decile of FL growth velocity. None of the other extreme deciles of fetal growth 
velocity were associated with the risk of sPTB (Table 4). There were no interactions 
between the lowest decile of FL growth velocity and any of the maternal 
characteristics on sPTB (likelihood ratio test P value >0.05 in all tests). None of the 
infants in the lowest decile of FL growth velocity who delivered preterm had a 
skeletal dysplasia. Eight babies who had sPTB were delivered by caesarean section. 
Our main findings persisted when they were excluded: babies in the lowest decile of 
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FL growth velocity had a 2.88 fold (95% CI: 1.73 to 4.81) risk of sPTB in the cause-
specific regression adjusted for maternal characteristics. 
 
DISCUSSION 
 
The key finding of the present study is that reduced growth velocity of the fetal femur 
between 20 and 28 weeks gestational age was associated with an increased risk of 
sPTB. The association was evident when FL growth velocity was treated as a 
continuous variable, and when it was dichotomised as the lowest decile of growth 
velocity. In the latter case, the risk of sPTB was increased by two to three fold. There 
was also a weak inverse association between an increase in EFW between 20 and 
28 weeks and sPTB. However, as EFW incorporates FL, this may simply be due to 
the same association, as there were no independent relations between the other 
biometric measures used to calculate the EFW and the risk of PTB. These data 
imply that the factors which lead to reduced growth of the fetal femur between 20 
and 28 weeks gestational age are also associated with the risk of sPTB. 
 
A number of previous studies have addressed the relationship between first and 
second trimester fetal growth and the risk of sPTB. The study that is most directly 
comparable with the present analysis is the Generation R cohort, which also 
performed serial ultrasonic fetal biometry (33). These authors reported a number of 
associations, some of which were also observed in the present study and some of 
which were not. Consistent with our study, they found that a decrease in the relative 
size of the fetal femur between 20 and 30 weeks gestational age was associated 
with an increased risk of sPTB. The observation and the magnitude of the 
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association were very similar to our findings. They also observed that higher values 
of fetal biometry at 20 weeks gestational age were associated with an increased risk 
of sPTB. In our study, associations of a similar magnitude were observed but they 
were statistically significant only in multivariate analysis. Moreover, they observed 
that reduced growth velocity (between ~20 and ~30 weeks) of both the HC and the 
AC were also associated with increased risks of sPTB, whereas we did not. There 
are multiple potential explanations for the discrepant results. The estimates for the 
association between AC growth velocity and sPTB were similar but since Generation 
R was a larger cohort, the statistical power to identify associations of this magnitude 
was higher. However, the estimated association between HC growth velocity and 
sPTB was clearly different. Some of the key differences in the Generation R cohort 
were that it included women of mixed parity, that 43% of the cohort was of non-
European ethnic origin, and that gestational age in that study was based on either 
the menstrual history or early ultrasound, depending on the availability of a reliable 
menstrual record. Further studies, or further analysis of the Generation R study, may 
help to explain the differences. However, the consistency of the findings with FL in 
both studies indicates that this association is very likely to be true and to be 
generalizable. 
 
When we analysed the association between biometry and the risk of sPTB, we 
studied the measurements both as continuous variables and by dichotomising them 
into the extreme decile associated with FGR. We used this approach because there 
may be different etiological associations between factors which cause variation 
across the whole range of the population, and the factors which lead to a small 
number of pregnancies having very low values. For example, if we assume that there 
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is some underlying pathological process that impairs growth of the fetal femur, it is 
most likely that only a small proportion of pregnancies would be so affected. It would 
also be expected that the 10% of pregnancies with the lowest value of FL growth 
velocity would include a much higher proportion of these pathological cases than the 
other 9 deciles. Hence, it might be expected that analysis of measures as continuous 
variables addresses primarily the effect of physiological variation in the parameter 
whereas analysis of measures by the most extreme decile addresses primarily 
pathological variation of the parameter. Interestingly, when we analysed fetal 
biometry using the most extreme decile, the only association we identified was 
between reduced FL growth velocity and sPTB.  
 
The observations described above suggest that there is a strong association 
between pathological determinants of an isolated short femur in the second trimester 
and the risk of sPTB. Interestingly, a series of papers have highlighted the 
association between isolated short femur and the risk of severe early onset fetal 
growth restriction (34, 41-43). Collectively, these observations suggest that poor 
growth of the femur in the second trimester may be a marker of an important 
underlying determinant of adverse pregnancy outcome. Previous studies have found 
an association between levels of blood biomarkers during pregnancy, such as 
pregnancy associated plasma protein A and alpha-fetoprotein, and both fetal growth 
restriction and sPTB (11-18). Both the biochemical and ultrasonic data indicate that 
the factors which lead to FGR may also lead to sPTB. There is a potentially plausible 
biological link. Growth restricted fetuses have activation of the stress pathway of the 
hypothalamopituitary adrenal (HPA) axis (44), and there is extensive evidence 
linking the HPA axis to the physiological control of the timing of parturition (45).  
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Studies of growth restriction distinguish between asymmetric growth restriction, 
where there is an increase in the size of the head to the size of the body and 
symmetric growth restriction, i.e. where the baby is small but the HC and AC are in 
proportion. A recent study reported symmetrically growth restricted babies having the 
greatest deviation from normal height and weight at aged 4 (46) and the authors 
speculated that symmetric growth restriction leading to PTB is due to early onset 
placental dysfunction. We have previously reported an association between low first 
trimester levels of pregnancy associated plasma protein A  and PTB (12). Early 
onset placental dysfunction might explain the observed association between reduced 
FL growth velocity and sPTB and we are planning to test this hypothesis in the 
future. 
 
A key strength of the POP study design is its prospective investigation of serial fetal 
biometric measures at consistent time points. Moreover, gestational age was 
measured using early pregnancy ultrasound. Spontaneous versus iatrogenic PTB 
was clearly defined and ascertained by trained midwives. To better capture the 
growth process, we assessed fetal growth velocity, defined as the change in fetal 
biometric measure z-score, between 20 and 28 weeks of gestational age. Most 
importantly, patients and care providers were blinded to the results of the 28 week 
scan. Hence, the associations between growth velocity and sPTB cannot be 
explained by biases related to knowledge of the scan result.  
 
We analysed the data using both cause-specific and competing risks approach. The 
former is preferred for answering etiologic questions (estimation of hazard ratios) 
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whereas the latter is preferred for prognostic questions (calculation of cumulative 
incidence). The focus of the present paper is on etiology but we present both 
approaches as recommended (47, 48). The number of competing events was small 
(n=59) and the two approaches gave very similar results. The proportion of missing 
values in the regression analyses varied between 5.7% and 11.7%, and we 
considered that imputation was not necessary as the bias resulting from missing 
values was probably small (49-51). Furthermore, we did not make adjustments to 
statistical significance levels, although we tested multiple hypotheses. This approach 
was adopted since our exposure measures of fetal biometry were correlated and our 
approach was hypothesis-driven. Moreover, the P value for the association between 
lowest decile of FL growth and sPTB was <0.001 and it is very unlikely that this could 
be a chance finding due to multiple comparisons.  
 
The cohort included the first pregnancies of predominantly healthy women from a 
relatively affluent area in the UK, which may partly explain the relatively low risk of 
sPTB. It is well recognised that rates of sPTB are much higher in the USA than the 
majority of high income countries and the reasons for this are incompletely 
understood. However, the association between fetal growth and sPTB will not 
necessarily be influenced by the overall prevalence of PTB. Slow growth in FL is 
unlikely to be simply a marker of maternal characteristics such as maternal height or 
ethnicity. Although maternal height was associated with both FL growth velocity and 
sPTB, adjustment for it had very little impact. We did not observe ethnic differences 
between the sPTB group and babies born at term. The proportion of non-white 
women was low in the population and we had inadequate statistical power to detect 
ethnic differences. The recent INTERGROWTH-21st project has indicated that 
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ethnicity per se has a relatively modest effect on variation in fetal growth (40). 
Therefore, it is unlikely to be a strong confounder even in ethnically heterogeneous 
populations. Maternal BMI and socio-economic status were not associated with 
sPTB in our study and this may be due to insufficient statistical power. 
 
Two main recognized subsets of sPTB include sPTB with intact membranes and 
preterm premature rupture of membranes. It has been recognized that the 
pathophysiologies of these are distinct (52, 53). While it might further be 
hypothesised that fetal growth may play a different role in each, we did not make a 
distinction between the two and nor have most other studies in this field. Given the 
low number of PTBs observed in the present study, additional splitting of the study 
population birth outcomes would have compromised power. This may be a useful 
avenue for future studies. 
 
In conclusion, we show that reduced growth velocity of the fetal femur between 20 
and 28 weeks of gestational is associated with an increased risk of sPTB. These 
data add to a body of evidence indicating that an isolated short femur could be a 
marker of early onset FGR, and that FGR may be an important determinant of 
apparently unexplained sPTB.  
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Table 1. Characteristics of Study Participants by Birth Outcome in the Pregnancy Outcome Prediction (POP) Study, Cambridge, UK, 2008-
2012. 
a Overall characteristics include all birth types in the study population: term, spontaneous preterm, iatrogenic preterm and unknown. Out of the total, 59 (1.5%) preterm births 
were iatrogenic, and data were missing on the nature of 9 (0.2%) births.  
b Continuous variables were compared between term births and spontaneous preterm births using the Wilcoxon rank-sum test, and binary variables using Pearson's chi-
squared test (apart from previous therapeutic abortion which was compared with Fisher's exact test due to small cell counts). With the exception of Pearson’s chi-squared test, 
all tests for significance were two-sided, 
c BMI given as kg/m2.  
  Overalla Terma Spontaneous preterma Pb 
  No. % Median (IQR) No. % Median (IQR) No. % Median (IQR)   
Outcome 
          
Total births 3,892 100 
 
3,726 96 
 
98 2.5 
  
Gestational age at birth (weeks) 
 
 
40.3 (39.3- 41.1) 
 
 
40.4 (39.4-41.1) 
 
 
35.9 (34.7-36.4) 
 
Characteristics 
          Age (years)  
 
 
30.3 (26.8-33.3) 
 
 
30.3 (26.8-33.3) 
 
 
30.8 (27.3-33.7) 0.23 
Height (cm)  
 
 
165 (161-169) 
 
 
165 (161-170) 
 
 
164 (159-167) 0.005 
BMIc 
 
 
24.0 (21.8-27.2) 
 
 
24.0 (21.8-27.2) 
 
 
24.3 (22.5-26.4) 0.75 
Previous spontaneous abortion  
          Yes 396 10 
 
375 10 
 
9 9.2 
 
 No 3,496 90 
 
3,351 90 
 
89 91 
 
0.78 
Previous therapeutic abortion 
          Yes 35 0.9 
 
35 0.9 
 
0 0 
 
 No  3,857 99 
 
3,691 99 
 
98 100 
 
>0.99 
White ethnicity 
          Yes 3,620 93 
 
3,469 93 
 
89 91 
 
 No  210 5.4 
 
201 5.4 
 
7 7.1 
 
0.44 
Missing 62 1.6 
 
56 1.5 
 
2 2 
 
 Smoker 
          Yes 183 4.7 
 
174 4.7 
 
6 6.1 
 
 No 3,709 95 
 
3,552 95 
 
92 94 
 
0.5 
Married 
          Yes 2,670 69 
 
2,547 68 
 
68 69 
 
 No  1,220 31 
 
1,179 32 
 
30 31 
 
0.83 
Age discontinued full-time education 
(years)  
 
 
21 (18-23) 
 
 
21 (18-23) 
 
 
21 (18-23) 0.81 
Index of Multiple Deprivation      8.9 (5.7-14.2)     8.9 (5.7-14.2)     8.9 (5.6-12.2) 0.71 
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Table 2. Fetal Growth and the Risk of Spontaneous Preterm Birth in the Pregnancy Outcome Prediction (POP) Study, Cambridge, UK, 2008-
2012. 
 
 
Cause-specific regression  Competing risks regression 
 
Unadjusted Adjusteda   Unadjusted Adjusteda  
Measure n 
 
HR 95% CI Pb HR 95% CI Pb 
 
sHR 95% CI Pb sHR 95% CI Pb 
Fetal biometry at 20 weeksc                
Head circumference 3,619  1.19 0.97, 1.46 0.10 1.22 0.99, 1.49 0.06  1.19 0.98, 1.44 0.08 1.22 1.01, 1.47 0.04 
Abdominal circumference 3,660  1.18 0.96, 1.45 0.12 1.20 0.98, 1.48 0.08  1.18 0.96, 1.44 0.12 1.21 0.98, 1.48 0.07 
Femur length 3,667  1.12 0.92, 1.36 0.28 1.18 0.96, 1.44 0.12  1.12 0.91, 1.38 0.28 1.18 0.96, 1.46 0.13 
Estimated fetal weight 3,658  1.20 0.99, 1.47 0.06 1.26 1.03, 1.54 0.02  1.21 0.99, 1.47 0.06 1.27 1.04, 1.54 0.02 
HC:AC ratio 3,609  0.95 0.77, 1.18 0.66 0.95 0.77, 1.18 0.66  0.95 0.76, 1.20 0.68 0.95 0.75, 1.20 0.68 
AC:FL ratio 3,658  1.03 0.84, 1.26 0.80 1.00 0.82, 1.23 0.98  1.03 0.84, 1.25 0.80 1.00 0.82, 1.22 0.98 
Fetal growth velocity from 
20 to 28 weeksc 
 
 
      
 
      
Δ Head circumference 3,445  0.85 0.67, 1.06 0.15 0.86  0.68, 1.09 0.21  0.85 0.68, 1.08 0.18 0.87 0.68, 1.11 0.21 
Δ Abdominal circumference 3,656  0.91 0.74, 1.10 0.33 0.90 0.74, 1.10 0.32  0.91 0.75, 1.11 0.34 0.91 0.74, 1.11 0.34 
Δ Femur length 3,662  0.73 0.60, 0.89 0.002 0.73 0.59, 0.89 0.002  0.74 0.60, 0.90 0.004 0.73 0.58, 0.92 0.007 
Δ Estimated fetal weight 3,654  0.79 0.64, 0.99 0.04 0.79 0.63, 0.99 0.04  0.80 0.64, 0.99 0.04 0.79 0.63, 0.99 0.05 
Δ HC:AC ratio 3,433  0.98 0.81, 1.17 0.80 0.98 0.81, 1.18 0.83  0.98 0.80, 1.19 0.83 0.98 0.80, 1.20 0.84 
Δ AC:FL ratio 3,651  1.16 0.97, 1.38 0.11 1.16 0.97, 1.40 0.11  1.16 0.96, 1.40 0.13 1.16 0.96, 1.42 0.13 
Fetal biometry at 28 weeksc                
Head circumferenced 3,490  1.02 0.82, 1.27 0.85 1.07 0.86, 1.33 0.57  1.03 0.81, 1.31 0.83 1.07 0.84, 1.37 0.58 
Abdominal circumference 3,670  1.06 0.86, 1.29 0.60 1.08 0.88, 1.33 0.47  1.06 0.87, 1.30 0.58 1.09 0.88, 1.34 0.44 
Femur length 3,669  0.81 0.66, 0.99 0.04 0.85 0.68, 1.05 0.12  0.81 0.65, 1.02 0.08 0.85 0.67, 1.09 0.20 
Estimated fetal weight 3,670  0.99 0.81, 1.22 0.96 1.04 0.85, 1.28 0.70  1.00 0.81, 1.23 0.96 1.05 0.84, 1.30 0.67 
HC:AC ratio 3,488  0.99 0.80, 1.23 0.96 0.99 0.80, 1.22 0.93  1.00 0.79, 1.25 0.97 0.99 0.79, 1.24 0.93 
AC:FL ratio 3,667  1.23 1.01, 1.51 0.04 1.21 0.99, 1.49 0.06  1.23 0.99, 1.54 0.06 1.21 0.97, 1.52 0.09 
 
Abbreviations: AC, abdominal circumference; CI, confidence interval; FL, femur length; HC, head circumference; HR, hazard ratio; sHR, ratio of the subdistribution hazards.  
a Adjusted for maternal height, age, BMI, marital status, previous spontaneous abortion, ethnicity, smoking status, age at leaving full time education and Index of Multiple 
Deprivation (IMD).  
b P values are from the z test specific to each method, i.e. cause-specific or competing risks regression. All tests for significance were two-sided. 
c Fetal biometry and growth velocity measures are expressed in z-scores estimated in the POP study and therefore hazard ratios are given per one standard deviation increase 
in fetal biometry or growth velocity measure.  
d Departure from proportionality for week 28 head circumference was detected in the unadjusted cause-specific regression (Schoenfeld test P=0.01) and competing risks 
regression (z test for interaction with follow-up time P=0.008).   
26 
 
Table 3. Fetal Growth and the Risk of Spontaneous Preterm Birth, Using an International Reference Standard in the Pregnancy Outcome 
Prediction (POP) Study, Cambridge, UK, 2008-2012. 
 
 
Cause-specific regression  Competing risks regression 
 
Unadjusted Adjusteda   Unadjusted Adjusteda  
Measure n 
 
HR 95% CI Pb HR 95% CI Pb 
 
sHR 95% CI Pb sHR 95% CI Pb 
Fetal biometry at 20 weeksc                
Head circumference 3,619  1.24 0.95, 1.62 0.12 1.28 0.98, 1.67 0.07  1.24 0.97, 1.59 0.09 1.28 1.00, 1.64 0.05 
Abdominal circumference 3,660  1.22 0.94, 1.57 0.13 1.25 0.97, 1.62 0.09  1.22 0.95, 1.57 0.12 1.26 0.98, 1.61 0.08 
Femur length 3,667  1.14 0.89, 1.45 0.29 1.21 0.95, 1.55 0.12  1.14 0.89, 1.46 0.30 1.22 0.94, 1.57 0.13 
Fetal growth velocity from 
20 to 28 weeksc 
 
 
      
 
      
Δ Head circumference 3,445  0.87 0.67, 1.11 0.26 0.89 0.69, 1.15 0.38  0.87 0.67, 1.15 0.33 0.90 0.68, 1.19 0.46 
Δ Abdominal circumference 3,656  0.92 0.75, 1.14 0.47 0.93 0.75, 1.15 0.49  0.93 0.75, 1.15 0.49 0.93 0.74, 1.16 0.52 
Δ Femur length 3,662  0.72 0.58, 0.89 0.002 0.72 0.58, 0.90 0.003  0.72 0.58, 0.91 0.006 0.73 0.57, 0.93 0.01 
Fetal biometry at 28 weeksc                
Head circumferenced 3,490  1.02 0.82, 1.26 0.86 1.06 0.86, 1.32 0.57  1.03 0.81, 1.30 0.83 1.07 0.84, 1.36 0.59 
Abdominal circumference 3,670  1.05 0.86, 1.28 0.62 1.08 0.88, 1.32 0.48  1.06 0.87, 1.29 0.59 1.08 0.88, 1.33 0.46 
Femur length 3,669  0.82 0.67, 1.00 0.05 0.86 0.70, 1.05 0.13  0.83 0.67, 1.02 0.08 0.86 0.69, 1.08 0.20 
 
Abbreviations: AC, abdominal circumference; CI, confidence interval; FL, femur length; HC, head circumference; HR, hazard ratio; sHR, ratio of the subdistribution hazards.  
a Adjusted for maternal height, age, BMI, marital status, previous spontaneous abortion, ethnicity, smoking status, age at leaving time education and Index of Multiple 
Deprivation (IMD).  
b P values are from the z test specific to each method, i.e. cause-specific or competing risks regression.  All tests for significance were two-sided. 
c Fetal biometry and growth velocity measures are expressed in z-scores with respect to the INTERGROWTH-21st Project reference. Hazard ratios are given per one standard 
deviation increase in fetal biometry or growth velocity measure according to the international reference. Median percentiles (interquartile range) in the POP Study at 20 weeks 
were HC: 52.8 (32.8 to 71.7), AC: 66.6 (44.4 to 83.0), FL: 48.0 (30.7 to 73.3) and at 28 weeks were HC: 73.4 (46.9 to 90.2), AC: 66.1 (40.3 to 86.7)), FL: 53.2 (27.4 to 79.1). 
Median percentiles (interquartile range) of changes from 20 to 28 weeks were ΔHC: 70.8 (50.0 to 86.1), ΔAC: 51.9 (27.1 to 74.3) and ΔFL: 53.8 (27.6 to 76.4). 
d Departure from proportionality for week 28 head circumference was detected in the unadjusted cause-specific regression (Schoenfeld test P=0.01) and competing risks 
regression (z test for interaction with follow-up time P=0.008).   
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Table 4. Fetal Growth and the Risk of Spontaneous Preterm Birth, with Growth Expressed as Extreme Decile Indicative of Impaired Growth in 
the Pregnancy Outcome Prediction (POP) Study, Cambridge, UK, 2008-2012. 
 
 
Cause-specific regression  Competing risks regression 
 
Unadjusted Adjusteda  Unadjusted Adjusteda 
Measure n 
 
HR 95% CI Pb HR 95% CI Pb 
 
sHR 95% CI Pb sHR 95% CI Pb 
Fetal biometry at 20 weeksc                
Head circumference 3,619  0.45 0.17, 1.23 0.12 0.41 0.15, 1.13 0.09  0.45 0.17, 1.23 0.12 0.41 0.15, 1.15 0.09 
Abdominal circumference 3,660  0.79 0.36, 1.70 0.54 0.75 0.34, 1.62 0.46  0.77 0.36, 1.67 0.52 0.74 0.34, 1.58 0.43 
Femur length 3,667  0.79 0.37, 1.72 0.56 0.72 0.33, 1.55 0.40  0.79 0.37, 1.71 0.55 0.71 0.33, 1.54 0.39 
Estimated fetal weight 3,658  0.89 0.43, 1.83 0.74 0.84 0.41, 1.74 0.64  0.88 0.42, 1.81 0.72 0.83 0.40, 1.71 0.62 
HC:AC ratio 3,609  1.19 0.62, 2.30 0.60 1.22 0.63, 2.35 0.56  1.19 0.62, 2.30 0.60 1.22 0.63, 2.36 0.56 
AC:FL ratio 3,658  1.01 0.51, 2.00 0.98 1.05 0.53, 2.10 0.89  1.01 0.51, 2.00 0.99 1.05 0.53, 2.10 0.89 
Fetal growth velocity from 
20 to 28 weeksc 
 
 
      
 
      
Δ Head circumference 3,445  1.30 0.67, 2.53 0.43 1.26 0.65, 2.45 0.49  1.27 0.66, 2.47 0.48 1.24 0.64, 2.42 0.53 
Δ Abdominal circumference 3,656  1.12 0.58, 2.16 0.74 1.12 0.58, 2.17 0.73  1.12 0.58, 2.16 0.74 1.13 0.58, 2.18 0.73 
Δ Femur length 3,662  2.37 1.43, 3.93 <0.001 2.50 1.50, 4.14 <0.001  2.36 1.42, 3.91 0.001 2.48 1.48, 4.17 0.001 
Δ Estimated fetal weight 3,654  1.24 0.66, 2.33 0.50 1.26 0.67, 2.37 0.47  1.23 0.65, 2.31 0.53 1.25 0.66, 2.35 0.49 
Δ HC:AC ratio 3,433  0.85 0.39, 1.85 0.69 0.87 0.40, 1.89 0.73  0.86 0.39, 1.86 0.69 0.87 0.40, 1.91 0.73 
Δ AC:FL ratio 3,651  0.85 0.41, 1.75 0.65 0.86 0.42, 1.78 0.69  0.85 0.41, 1.75 0.66 0.87 0.42, 1.81 0.70 
Fetal biometry at 28 weeksc                
Head circumference 3,490  1.13 0.56, 2.25 0.73 1.04 0.52, 2.08 0.92  1.11 0.55, 2.21 0.77 1.02 0.51, 2.06 0.95 
Abdominal circumference 3,670  0.66 0.29, 1.51 0.32 0.62 0.27, 1.43 0.27  0.64 0.28, 1.48 0.30 0.61 0.27, 1.40 0.24 
Femur length 3,669  1.55 0.88, 2.73 0.13 1.41 0.79, 2.51 0.24  1.53 0.87, 2.70 0.14 1.39 0.78, 2.49 0.26 
Estimated fetal weight 3,670  1.02 0.51, 2.02 0.96 0.93 0.46, 1.86 0.83  0.99 0.50, 1.98 0.99 0.91 0.44, 1.85 0.79 
HC:AC ratio 3,488  0.98 0.48, 2.04 0.97 0.97 0.47, 2.02 0.95  0.98 0.47, 2.04 0.96 0.97 0.47, 2.02 0.93 
AC:FL ratio 3,667  0.89 0.43, 1.83 0.75 0.93 0.45, 1.93 0.84  0.89 0.43, 1.83 0.75 0.93 0.45, 1.92 0.85 
 
Abbreviations: AC, abdominal circumference; CI, confidence interval; FL, femur length; HC, head circumference; HR, hazard ratio; sHR, ratio of the subdistribution hazards.  
a Adjusted for maternal height, age, BMI, marital status, previous spontaneous abortion, ethnicity, smoking status, age at leaving full time education and Index of Multiple 
Deprivation (IMD). 
b P values are from the z test specific to each method, i.e. cause-specific or competing risks regression. All tests for significance were two-sided.  
c Fetal biometry and growth velocity measures were expressed in z-scores estimated in the POP study and dichotomized to the clinically-relevant extreme decile versus the 
rest.  
d Extreme decile cut-off points of z-scores at 20 weeks were HC -1.2835, AC -1.2807, FL: -1.2136, EFW: -1.2640, HC:AC ratio: 1.3296, AC:FL ratio: -1.3030 and at 28 weeks 
were HC -1.2588, AC -1.2780, FL: -1.2517, EFW: -1.2378, HC:AC ratio: 1.2717, AC:FL ratio: -1.2638. Extreme decile cut-off points of z-score changes from 20 to 28 weeks 
were ΔHC: -1.1949, ΔAC:-1.3289, ΔFL: -1.3020, ΔEFW: -1.1640, ΔHC:AC ratio: 1.4960, ΔAC:FL ratio: -1.4823. 
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d Hazard ratio associated with being in the lowest decile of each measurement versus the rest was calculated for all measures except for HC:AC ratio and Δ HC:AC ratio, 
where the highest decile was compared with the rest. 
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Fig 1. Cumulative incidence (births/100 women) of spontaneous preterm birth 
between 28+0/7 and 36+6/7 weeks of gestational age in the Pregnancy Outcome 
Prediction (POP) Study, Cambridge, UK, 2008-2012, comparing fetuses with the 
lowest decile of femur length growth velocity between 20 and 28 weeks (solid line) 
and all other fetuses (dashed line) using the competing risks method (P=0.001).  
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